newsfilter
← Latest News
Business Wire·

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and a substantially